Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Trametinib inhibits RAS-mutant MLL-rearranged acute lymphoblastic leukemia at specific niche sites and reduces ERK phosphorylation in vivo.

Literature DB >> 29419436

Trametinib inhibits RAS-mutant MLL-rearranged acute lymphoblastic leukemia at specific niche sites and reduces ERK phosphorylation in vivo.

Mark Kerstjens¹, Sandra S Pinhancos², Patricia Garrido Castro², Pauline Schneider², Priscilla Wander², Rob Pieters², Ronald W Stam³.

Abstract

Entities: Chemical Disease Gene

Mesh：

Substances：

Year: 2018 PMID： 29419436 PMCID： PMC5865421 DOI： 10.3324/haematol.2017.174060

Source DB: PubMed Journal: Haematologica ISSN： 0390-6078 Impact factor: 9.941

× No keyword cloud information.

14 in total

1. Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia.

Authors: M Dördelmann; A Reiter; A Borkhardt; W D Ludwig; N Götz; S Viehmann; H Gadner; H Riehm; M Schrappe
Journal: Blood Date: 1999-08-15 Impact factor: 22.113

2. Relation between age, immunophenotype and in vitro drug resistance in 395 children with acute lymphoblastic leukemia--implications for treatment of infants.

Authors: R Pieters; M L den Boer; M Durian; G Janka; K Schmiegelow; G J Kaspers; E R van Wering; A J Veerman
Journal: Leukemia Date: 1998-09 Impact factor: 11.528

3. Subclonality and prenatal origin of RAS mutations in KMT2A (MLL)-rearranged infant acute lymphoblastic leukaemia.

Authors: Mariana Emerenciano; Thayana da C Barbosa; Bruno de Almeida Lopes; Claus Meyer; Rolf Marschalek; Maria S Pombo-de-Oliveira
Journal: Br J Haematol Date: 2015-01-22 Impact factor: 6.998

4. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.

Authors: Alexander M Menzies; Georgina V Long
Journal: Clin Cancer Res Date: 2014-02-28 Impact factor: 12.531

5. Inhibition of the growth of patient-derived pancreatic cancer xenografts with the MEK inhibitor trametinib is augmented by combined treatment with the epidermal growth factor receptor/HER2 inhibitor lapatinib.

Authors: Dustin M Walters; James M Lindberg; Sara J Adair; Timothy E Newhook; Catharine R Cowan; Jayme B Stokes; Cheryl A Borgman; Edward B Stelow; Bryce T Lowrey; Maria E Chopivsky; Tona M Gilmer; John T Parsons; Todd W Bauer
Journal: Neoplasia Date: 2013-02 Impact factor: 5.715

6. Frequencies and prognostic impact of RAS mutations in MLL-rearranged acute lymphoblastic leukemia in infants.

Authors: Emma M C Driessen; Eddy H J van Roon; Jill A P Spijkers-Hagelstein; Pauline Schneider; Paola de Lorenzo; Maria Grazia Valsecchi; Rob Pieters; Ronald W Stam
Journal: Haematologica Date: 2013-02-12 Impact factor: 9.941

7. Activated KRAS Cooperates with MLL-AF4 to Promote Extramedullary Engraftment and Migration of Cord Blood CD34+ HSPC But Is Insufficient to Initiate Leukemia.

Authors: Cristina Prieto; Ronald W Stam; Antonio Agraz-Doblas; Paola Ballerini; Mireia Camos; Julio Castaño; Rolf Marschalek; Aldeheid Bursen; Ignacio Varela; Clara Bueno; Pablo Menendez
Journal: Cancer Res Date: 2016-02-02 Impact factor: 12.701

8. MEK inhibition is a promising therapeutic strategy for MLL-rearranged infant acute lymphoblastic leukemia patients carrying RAS mutations.

Authors: Mark Kerstjens; Emma M C Driessen; Merel Willekes; Sandra S Pinhanços; Pauline Schneider; Rob Pieters; Ronald W Stam
Journal: Oncotarget Date: 2017-02-28

9. MEK inhibitors potentiate dexamethasone lethality in acute lymphoblastic leukemia cells through the pro-apoptotic molecule BIM.

Authors: A A Rambal; Z L G Panaguiton; L Kramer; S Grant; H Harada
Journal: Leukemia Date: 2009-04-30 Impact factor: 11.528

10. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial.

Authors: Rob Pieters; Martin Schrappe; Paola De Lorenzo; Ian Hann; Giulio De Rossi; Maria Felice; Liisa Hovi; Thierry LeBlanc; Tomasz Szczepanski; Alice Ferster; Gritta Janka; Jeffrey Rubnitz; Lewis Silverman; Jan Stary; Myriam Campbell; Chi-Kong Li; Georg Mann; Ram Suppiah; Andrea Biondi; Ajay Vora; Maria Grazia Valsecchi
Journal: Lancet Date: 2007-07-21 Impact factor: 79.321

11 in total

1. Inhibition of MEK and ATR is effective in a B-cell acute lymphoblastic leukemia model driven by Mll-Af4 and activated Ras.

Authors: S Haihua Chu; Evelyn J Song; Jonathan R Chabon; Janna Minehart; Chloe N Matovina; Jessica L Makofske; Elizabeth S Frank; Kenneth Ross; Richard P Koche; Zhaohui Feng; Haiming Xu; Andrei Krivtsov; Andre Nussenzweig; Scott A Armstrong
Journal: Blood Adv Date: 2018-10-09

2. Pediatric ALL relapses after allo-SCT show high individuality, clonal dynamics, selective pressure, and druggable targets.

Authors: Jessica I Hoell; Sebastian Ginzel; Michaela Kuhlen; Andreas Kloetgen; Michael Gombert; Ute Fischer; Daniel Hein; Salih Demir; Martin Stanulla; Martin Schrappe; Udo Zur Stadt; Peter Bader; Florian Babor; Friedhelm Schuster; Brigitte Strahm; Julia Alten; Anja Moericke; Gabriele Escherich; Arend von Stackelberg; Ralf Thiele; Alice C McHardy; Christina Peters; Beat Bornhauser; Jean-Pierre Bourquin; Stefan Krause; Juergen Enczmann; Lüder Hinrich Meyer; Cornelia Eckert; Arndt Borkhardt; Roland Meisel
Journal: Blood Adv Date: 2019-10-22

3. Novel Diagnostic and Therapeutic Options for KMT2A-Rearranged Acute Leukemias.

Authors: Bruno A Lopes; Caroline Pires Poubel; Cristiane Esteves Teixeira; Aurélie Caye-Eude; Hélène Cavé; Claus Meyer; Rolf Marschalek; Mariana Boroni; Mariana Emerenciano
Journal: Front Pharmacol Date: 2022-06-06 Impact factor: 5.988

4. Activating KRAS, NRAS, and BRAF mutants enhance proteasome capacity and reduce endoplasmic reticulum stress in multiple myeloma.

Authors: Fazal Shirazi; Richard J Jones; Ram K Singh; Jianxuan Zou; Isere Kuiatse; Zuzana Berkova; Hua Wang; Hans C Lee; Samuel Hong; Larry Dick; Nibedita Chattopadhyay; Robert Z Orlowski
Journal: Proc Natl Acad Sci U S A Date: 2020-08-03 Impact factor: 11.205

5. Constitutive Activation of RAS/MAPK Pathway Cooperates with Trisomy 21 and Is Therapeutically Exploitable in Down Syndrome B-cell Leukemia.

Authors: Anouchka P Laurent; Aurélie Siret; Cathy Ignacimouttou; Kunjal Panchal; M'Boyba Diop; Silvia Jenni; Yi-Chien Tsai; Damien Roos-Weil; Zakia Aid; Nais Prade; Stephanie Lagarde; Damien Plassard; Gaelle Pierron; Estelle Daudigeos; Yann Lecluse; Nathalie Droin; Beat C Bornhauser; Laurence C Cheung; John D Crispino; Muriel Gaudry; Olivier A Bernard; Elizabeth Macintyre; Carole Barin Bonnigal; Rishi S Kotecha; Birgit Geoerger; Paola Ballerini; Jean-Pierre Bourquin; Eric Delabesse; Thomas Mercher; Sebastien Malinge
Journal: Clin Cancer Res Date: 2020-03-27 Impact factor: 12.531

6. Aurora B kinase as a therapeutic target in acute lymphoblastic leukemia.

Authors: Hiroaki Goto; Yuki Yoshino; Mieko Ito; Junichi Nagai; Tadashi Kumamoto; Takesi Inukai; Yukari Sakurai; Naoyuki Miyagawa; Dai Keino; Tomoko Yokosuka; Fuminori Iwasaki; Satoshi Hamanoue; Masae Shiomi; Shoko Goto
Journal: Cancer Chemother Pharmacol Date: 2020-03-06 Impact factor: 3.333

10. Successful use of trametinib and dasatinib combined with chemotherapy in the treatment of Ph-positive B-cell acute lymphoblastic leukemia: A case report.

Authors: Jing Wang; Shu-Hong Shen; Bin-Fei Hu; Guan-Ling Wang
Journal: Medicine (Baltimore) Date: 2021-06-25 Impact factor: 1.889